Systems Biology and Biomarkers of Early Effects for Occupational Exposure Limit Setting
暂无分享,去创建一个
Stephen W. Edwards | Eileen Kuempel | Lynne T. Haber | D. Gayle DeBord | Russell S. Thomas | L. Burgoon | L. Haber | E. Kuempel | Lyle Burgoon | B. Yucesoy | Berran Yucesoy | M. Helen Kanitz | M. H. Kanitz | D. Debord
[1] K. Wallace,et al. Dose response considerations in risk assessment--an overview of recent ILSI activities. , 2008, Toxicology letters.
[2] Michael B. Black,et al. A comprehensive statistical analysis of predicting in vivo hazard using high-throughput in vitro screening. , 2012, Toxicological sciences : an official journal of the Society of Toxicology.
[3] C. Wild. Complementing the Genome with an “Exposome”: The Outstanding Challenge of Environmental Exposure Measurement in Molecular Epidemiology , 2005, Cancer Epidemiology Biomarkers & Prevention.
[4] Michael B. Black,et al. Cross-species comparisons of transcriptomic alterations in human and rat primary hepatocytes exposed to 2,3,7,8-tetrachlorodibenzo-p-dioxin. , 2012, Toxicological sciences : an official journal of the Society of Toxicology.
[5] A. Hubbard,et al. Toxicogenomic profiling of chemically exposed humans in risk assessment. , 2010, Mutation research.
[6] Conrad Brunk,et al. Guidelines for the communication of Biomonitoring Equivalents: report from the Biomonitoring Equivalents Expert Workshop. , 2008, Regulatory toxicology and pharmacology : RTP.
[7] David M. Reif,et al. Endocrine Profiling and Prioritization of Environmental Chemicals Using ToxCast Data , 2010, Environmental health perspectives.
[8] F Kalberlah,et al. Time extrapolation and interspecies extrapolation for locally acting substances in case of limited toxicological data. , 2002, The Annals of occupational hygiene.
[9] R. Scheuplein,et al. Differential Sensitivity of Children and Adults to Chemical Toxicity , 2004, Human and Ecological Risk Assessment: An International Journal.
[10] I. Rusyn,et al. Computational Toxicology: Realizing the Promise of the Toxicity Testing in the 21st Century , 2010, Environmental health perspectives.
[11] P. Biswas,et al. Concept of Assessing Nanoparticle Hazards Considering Nanoparticle Dosemetric and Chemical/Biological Response Metrics , 2010, Journal of toxicology and environmental health. Part A.
[12] Jeffrey Fisher,et al. Interpreting NHANES biomonitoring data, cadmium. , 2010, Toxicology letters.
[13] Wei Zhang,et al. Epigenetic Regulation in Particulate Matter-Mediated Cardiopulmonary Toxicities: A Systems Biology Perspective. , 2012, Current pharmacogenomics and personalized medicine.
[14] Kenny S. Crump,et al. Calculation of Benchmark Doses from Continuous Data , 1995 .
[15] Patricia Ruiz,et al. SAR/QSAR methods in public health practice. , 2011, Toxicology and applied pharmacology.
[16] D. Dix,et al. Informing Selection of Nanomaterial Concentrations for ToxCast in Vitro Testing Based on Occupational Exposure Potential , 2011, Environmental health perspectives.
[17] H. Dosaka-akita,et al. Pneumoconiosis-related lung cancers: preferential occurrence from diffuse interstitial fibrosis-type pneumoconiosis. , 2000, American journal of respiratory and critical care medicine.
[18] Peter J Boogaard,et al. Human biomonitoring as a pragmatic tool to support health risk management of chemicals--examples under the EU REACH programme. , 2011, Regulatory toxicology and pharmacology : RTP.
[19] L. Lesko,et al. Use of biomarkers and surrogate endpoints in drug development and regulatory decision making: criteria, validation, strategies. , 2001, Annual review of pharmacology and toxicology.
[20] D. Dix,et al. The ToxCast program for prioritizing toxicity testing of environmental chemicals. , 2007, Toxicological sciences : an official journal of the Society of Toxicology.
[21] Thomas A. Louis,et al. What Role for Biologically Based Dose–Response Models in Estimating Low-Dose Risk? , 2010, Environmental health perspectives.
[22] Annie M. Jarabek,et al. CONSIDERATION OF TEMPORAL TOXICITY CHALLENGES CURRENT DEFAULT ASSUMPTIONS , 1995 .
[23] Melvin E Andersen,et al. New directions in incidence-dose modeling. , 2005, Trends in biotechnology.
[24] D. Noble,et al. Systems Biology: An Approach , 2010, Clinical pharmacology and therapeutics.
[25] P. Nelson,et al. Microarray bioinformatics. , 2011, Methods in molecular biology.
[26] B. Allen,et al. Evidence-based dose-response assessment for thyroid tumorigenesis from acrylamide. , 2008, Regulatory toxicology and pharmacology : RTP.
[27] W. Lutz,et al. Susceptibility differences in chemical carcinogenesis linearize the dose-response relationship: threshold doses can be defined only for individuals. , 2001, Mutation research.
[28] Aldons J. Lusis,et al. Metabolic syndrome: from epidemiology to systems biology , 2008, Nature Reviews Genetics.
[29] Robert J Kavlock,et al. Computational toxicology--a state of the science mini review. , 2008, Toxicological sciences : an official journal of the Society of Toxicology.
[30] D. Wishart. Applications of Metabolomics in Drug Discovery and Development , 2008, Drugs in R&D.
[31] E. Lander,et al. Meta-analysis of genetic association studies supports a contribution of common variants to susceptibility to common disease , 2003, Nature Genetics.
[32] R J Smith,et al. Methodologic issues in using epidemiologic studies of occupational cohorts for cancer risk assessment. , 1992, Epidemiologia e prevenzione.
[33] Melvin E. Andersen,et al. Temporal concordance between apical and transcriptional points of departure for chemical risk assessment. , 2013, Toxicological sciences : an official journal of the Society of Toxicology.
[34] B. Allen,et al. Use of Early Effect Biomarker Data to Enhance Dose-Response Models of Lung Tumors in Rats Exposed to Titanium Dioxide , 2013 .
[35] P. Borm,et al. Concordance Between In Vitro and In Vivo Dosimetry in the Proinflammatory Effects of Low-Toxicity, Low-Solubility Particles: The Key Role of the Proximal Alveolar Region , 2008, Inhalation toxicology.
[36] Roel P F Schins,et al. Genotoxicity of Poorly Soluble Particles , 2007, Inhalation toxicology.
[37] L. Stayner,et al. Rat- and human-based risk estimates of lung cancer from occupational exposure to poorly-soluble particles: A quantitative evaluation , 2009 .
[38] J. Bailar,et al. Toxicity Testing in the 21st Century: A Vision and a Strategy , 2010, Journal of toxicology and environmental health. Part B, Critical reviews.
[39] G. Churchill,et al. Statistical design and the analysis of gene expression microarray data. , 2007, Genetical research.
[40] Michael I. Luster,et al. A Statistical Model for Assessing Genetic Susceptibility as a Risk Factor in Multifactorial Diseases: Lessons from Occupational Asthma , 2006, Environmental health perspectives.
[41] Tracey J. Woodruff,et al. Estimating Risk from Ambient Concentrations of Acrolein across the United States , 2006, Environmental health perspectives.
[42] Xingming Zhao,et al. Computational Systems Biology , 2013, TheScientificWorldJournal.
[43] D. Hattis,et al. Distributions of Individual Susceptibility among Humans for Toxic Effects: How Much Protection Does the Traditional Tenfold Factor Provide for What Fraction of Which Kinds of Chemicals and Effects? , 1999, Annals of the New York Academy of Sciences.
[44] Rory B Conolly,et al. The use of biologically based modeling in risk assessment. , 2002, Toxicology.
[45] Bruce A. Fowler,et al. Modification by ALAD of the Association between Blood Lead and Blood Pressure in the U.S. Population: Results from the Third National Health and Nutrition Examination Survey , 2009, Environmental health perspectives.
[46] J. Samet,et al. Invited Commentary: Epidemiology and Risk Assessment , 1998 .
[47] Alan R. Boobis,et al. IPCS Framework for Analyzing the Relevance of a Cancer Mode of Action for Humans , 2006 .
[48] Jonathan I Levy,et al. Science and Decisions: Advancing Risk Assessment , 2010, Risk analysis : an official publication of the Society for Risk Analysis.
[49] G L Kimmel,et al. Harmonization of cancer and noncancer risk assessment: proceedings of a consensus-building workshop. , 2001, Toxicological sciences : an official journal of the Society of Toxicology.
[50] B. Fowler. Biomarkers in toxicology and risk assessment. , 2012, Experientia supplementum.
[51] M. Stephens,et al. An Animal Protection Perspective On 21st Century Toxicology , 2010, Journal of toxicology and environmental health. Part B, Critical reviews.
[52] Melvin E Andersen,et al. Linear low-dose extrapolation for noncancer health effects is the exception, not the rule , 2011, Critical reviews in toxicology.
[53] A G Renwick,et al. Human variability and noncancer risk assessment--an analysis of the default uncertainty factor. , 1998, Regulatory toxicology and pharmacology : RTP.
[55] Andrew Maier,et al. A Bayesian Network Model for Biomarker‐Based Dose Response , 2010, Risk analysis : an official publication of the Society for Risk Analysis.
[56] Yuri Nikolsky,et al. Quantitative knowledge-based analysis in compound safety assessment , 2011, Expert opinion on drug metabolism & toxicology.
[57] Harvey J Clewell,et al. A method to integrate benchmark dose estimates with genomic data to assess the functional effects of chemical exposure. , 2007, Toxicological sciences : an official journal of the Society of Toxicology.
[58] N Mantel,et al. Fundamental carcinogenic processes and their implications for low-dose risk assessment. , 1978, Cancer research.
[59] E. Kuempel,et al. Occupational exposure to titanium dioxide , 2011 .
[60] Steven K. Gibb. Toxicity testing in the 21st century: a vision and a strategy. , 2008, Reproductive toxicology.
[61] Melvin E. Andersen,et al. New directions in toxicity testing. , 2011, Annual review of public health.
[62] Melvin E Andersen,et al. Computational Systems Biology and Dose-Response Modeling in Relation to New Directions in Toxicity Testing , 2010, Journal of toxicology and environmental health. Part B, Critical reviews.
[63] V. Vaidya,et al. Novel technologies for the discovery and quantitation of biomarkers of toxicity. , 2008, Toxicology.
[64] E. Schadt. Molecular networks as sensors and drivers of common human diseases , 2009, Nature.
[65] Marilyn J Aardema,et al. Toxicology and genetic toxicology in the new era of "toxicogenomics": impact of "-omics" technologies. , 2002, Mutation research.
[66] Ipcs,et al. Biomarkers in risk assessment: validity and validation , 2001 .
[67] J M Samet,et al. Epidemiology and risk assessment. , 1998, American journal of epidemiology.
[68] Philip J. Landrigan,et al. Biological markers in environmental health research , 1987 .
[69] Stephen W. Edwards,et al. Systems biology and mode of action based risk assessment. , 2008, Toxicological sciences : an official journal of the Society of Toxicology.
[70] A. Horii,et al. DNA methylation in cancer: a gene silencing mechanism and the clinical potential of its biomarkers. , 2013, The Tohoku journal of experimental medicine.
[71] Stephen W. Edwards,et al. Advancing the Next Generation of Health Risk Assessment , 2012, Environmental health perspectives.
[72] Andrew Maier,et al. Assessing Biomarker use in Risk Assessment—A Survey of Practitioners , 2004, Journal of toxicology and environmental health. Part A.
[73] R. Judson,et al. Estimating toxicity-related biological pathway altering doses for high-throughput chemical risk assessment. , 2011, Chemical research in toxicology.
[74] Ord,et al. A Review of the Reference Dose and Reference Concentration Processes , 2013 .
[75] 齊藤 宏之,et al. 海外研究紹介 Journal of Occupational and Environmental Hygiene , 2011 .
[76] Melvin E Andersen,et al. Toxicity testing in the 21st century: bringing the vision to life. , 2009, Toxicological sciences : an official journal of the Society of Toxicology.
[77] D Hattis,et al. Human interindividual variability--a major source of uncertainty in assessing risks for noncancer health effects. , 1994, Risk analysis : an official publication of the Society for Risk Analysis.
[78] Imran Shah,et al. Virtual Tissues in Toxicology , 2010, Journal of toxicology and environmental health. Part B, Critical reviews.
[79] Russell S. Thomas,et al. Application of transcriptional benchmark dose values in quantitative cancer and noncancer risk assessment. , 2011, Toxicological sciences : an official journal of the Society of Toxicology.
[80] J. Loeb,et al. Systems biology of human epilepsy applied to patients with brain tumors , 2013, Epilepsia.
[81] Ronald H. White,et al. State-of-the-Science Workshop Report: Issues and Approaches in Low-Dose–Response Extrapolation for Environmental Health Risk Assessment , 2008, Environmental health perspectives.
[82] Salomon Sand,et al. The Benchmark Dose Method—Review of Available Models, and Recommendations for Application in Health Risk Assessment , 2003, Critical reviews in toxicology.
[83] American Conference Of Governmental Industrial Hygienists 1998 Ventilation A O , 2019 .
[84] Michael Dourson,et al. Differential sensitivity of children and adults to chemical toxicity. II. Risk and regulation. , 2002, Regulatory toxicology and pharmacology : RTP.
[85] Susumu Goto,et al. KEGG for representation and analysis of molecular networks involving diseases and drugs , 2009, Nucleic Acids Res..
[86] Janet Woodcock,et al. Empowering microarrays in the regulatory setting , 2006, Nature Biotechnology.
[87] Paul A. Schulte,et al. Molecular epidemiology : principles and practices , 1993 .
[88] Andrew Maier,et al. Noncancer Risk Assessment: Principles and Practice in Environmental and Occupational Settings , 2012 .
[89] M. Sheffer,et al. CHARACTERIZATION AND APPLICATION OF PHYSIOLOGICALLY BASED PHARMACOKINETIC MODELS IN RISK ASSESSMENT , 2011 .
[90] R. Budinsky,et al. Human and rat primary hepatocyte CYP1A1 and 1A2 induction with 2,3,7,8-tetrachlorodibenzo-p-dioxin, 2,3,7,8-tetrachlorodibenzofuran, and 2,3,4,7,8-pentachlorodibenzofuran. , 2010, Toxicological sciences : an official journal of the Society of Toxicology.
[91] G. Oberdörster,et al. Nanotoxicology: in Vitro–in Vivo Dosimetry , 2012, Environmental health perspectives.
[92] 1986 Part II Environmental Protection Agency Guidelines for Carcinogen Risk Assessment , 2022 .
[93] R. Weinshilboum,et al. Metabolomics: a global biochemical approach to drug response and disease. , 2008, Annual review of pharmacology and toxicology.
[94] J. Fostel. Future of toxicogenomics and safety signatures: balancing public access to data with proprietary drug discovery. , 2007, Pharmacogenomics.
[95] Conrad Brunk,et al. Guidelines for the derivation of Biomonitoring Equivalents: report from the Biomonitoring Equivalents Expert Workshop. , 2008, Regulatory toxicology and pharmacology : RTP.
[96] S. Hays,et al. Biomonitoring-based risk assessment for hexabromocyclododecane (HBCD). , 2011, International journal of hygiene and environmental health.
[97] Bruce C Allen,et al. BMDExpress: a software tool for the benchmark dose analyses of genomic data , 2007, BMC Genomics.
[98] R. Hertzberg,et al. A new method for determining allowable daily intakes. , 1986, Fundamental and applied toxicology : official journal of the Society of Toxicology.
[99] J. Carter,et al. Effects of particle exposure and particle-elicited inflammatory cells on mutation in rat alveolar epithelial cells. , 1997, Carcinogenesis.
[100] Heck Hd. Noncancer Risk Assessment , 1994 .